Investors

We are committed to creating value for our society and our shareholders through life-changing peptide therapeutics for people who need them.

  • Shareholder portal
    • Zealand Pharma 0667

    • Share price information

      ZEAL (COP)

      372.20DKK

      Last updated on 23 June 2025 12:17 (GMT +01:00)

      Zealand Pharma is listed on Nasdaq Copenhagen under the ticker symbol ZEAL. Access investor information including full share price in DKK plus investor tools.

      More Stock information

    • Annual report 2024

      Zealand Pharm Lab Part 2 BF3I2859

      In 2024, we advanced our clinical-stage obesity portfolio, raised significant capital to further invest in our pipeline, and prepared the organization for the next phase of growth. Read our annual report.

      Download PDF

    • Corporate presentation

      Crosby CHI NJ USA JW 0875 B3A6034

      See Zealand Pharma's latest Corporate Presentation highlighting our R&D pipeline and additional company information.

      Download PDF
    Zealand Pharm Office Part 1 BF3I0028 2

    Catch up on our past events

    View the webcasts and documents from our past events here

    Past events

      69%

      of our operating expenditure focused on R&D in 2024

      15

      analysts covering Zealand Pharma

      71.0m

      shares outstanding as of December 31, 2024

      350+

      employees in Denmark and the United States

    Financial calendar

    See all financial events

    2025 Q1 Interim Report

    Latest financial report

    On May 8, 2025, Zealand Pharma reported results for the quarter ended March 31, 2025 and provided a company update.

  • Download PDF
  • All financial reports
    • Zealand Pharma 0425

    Latest news

    Newsroom
    • COMPANY ANNOUNCEMENT

      Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide

      READ MORE
    • COMPANY ANNOUNCEMENT

      Zealand Pharma increases its share capital as a result of the exercise of employee warrants

      READ MORE
    • PRESS RELEASE

      Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome

      READ MORE
    • COMPANY ANNOUNCEMENT

      Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

      READ MORE
    Zealand Pharma 1503

    Stay up-to-date with the latest news from Zealand

    Sign up to receive press releases and important company announcements directly to your inbox

    Subscribe

    • Corporate governance

      At Zealand Pharma, our corporate governance structure aims to support long-term financial performance, meet the obligations of our stakeholders, and create value for shareholders and society.

      Read more

    • Annual general meeting

      The Annual General Meeting for 2025 will be held on March 27th, 2025 at 15:00 CET. Find additional information on the AGM page.

      Read more

    • Analyst coverage

      Zealand Pharma is currently covered by 15 analysts and financial institutions across the U.S and Europe.

      Read more

    Safety, tolerability, and clinical effects of ZP8396, an amylin analog

    Featured publications

    Results from a 16-week Phase 1 multiple ascending dose (MAD) trial of petrelintide (ZP8396) presented at Obesity Week in October 2024.

  • Download PDF
  • All scientific publications
    • Zealand Pharma 0682

    An innovative R&D pipeline

    Obesity

    Petrelintide

    A long-acting amylin analog as a weight-loss medication representing an alternative to GLP-1 receptor agonists.

    READ MORE
    Obesity

    Dapiglutide

    A long-acting GLP-1/GLP-2 receptor dual agonist targeting obesity and low-grade inflammation.

    READ MORE
    Obesity

    Survodutide

    A long-acting glucagon/GLP-1 receptor dual agonist targeting obesity and MASH licensed to Boehringer Ingelheim.

    READ MORE
    Obesity

    ZP6590

    A GIP receptor agonist targeting obesity as a potential complement to GLP-1 for increased effect and/or tolerability.

    READ MORE
    Congenital Hyperinsulinism

    Dasiglucagon: Continuous infusion

    A glucagon analog designed to allow for continuous subcutaneous infusion via a wearable pump system for the treatment of Congenital Hyperinsulinism (CHI).

    READ MORE
    Short Bowel Syndrome

    Glepaglutide

    A long-acting GLP-2 analog designed to reduce or eliminate the need for parenteral support in SBS patients with intestinal failure.

    READ MORE
    Chronic inflammation

    ZP9830

    A potent and selective blocker of the Kv1.3 ion channel with the potential to treat a broad range of T-cell-driven autoimmune diseases.

    READ MORE
    Chronic inflammation

    ZP10068

    A long-acting inhibitor of the Complement C3 protein with the potential to target a broad range of complement-mediated diseases.

    READ MORE

    More investor information

    Investor relations policy

    We are committed to providing reliable and transparent information about our business, development programs and scientific results in a clear and timely manner.

  • Find our IR Policy

    • Prospectus

    Read our latest prospectus and prospectus summary from April 3, 2023.

  • Download prospectus summary
  • Download prospectus

    • Investor and Media contacts

    • Anna ALR0858

      Anna Krassowska

      Vice President, Investor Relations & Corporate Communications

      Email Anna

    You are about to leave Zealand Pharma's website

    The link below goes to a website not owned by Zealand Pharma:
  • Continue to external site
    • Zealand Pharma does not endorse the content of any such third-party website